Description: Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
Home Page: www.alumis.com
280 East Grand Avenue
South San Francisco,
CA
94080
United States
Phone:
650 231 6625
Officers
| Name | Title |
|---|---|
| Mr. Martin Babler Ph.D. | President, CEO & Chairman |
| Dr. David M. Goldstein Ph.D. | Chief Scientific Officer |
| Mr. Roy C. Hardiman J.D. | Chief Business Officer |
| Mr. John R. Schroer C.F.A. | Chief Financial Officer |
| Ms. Sara Klein | Chief Legal Officer & Corporate Secretary |
| Ms. Claire Langrish Ph.D. | Senior VP & Head of Immunology and Translational Science |
| Mr. Philip Nunn Ph.D. | Senior VP of Pharmacology & Project Team Leader |
| Dr. Jorn Drappa M.D., Ph.D. | Chief Medical Officer |
| Mr. Mark Bradley | Chief Development Officer |
| Mr. Kolbot By Ph.D. | Senior VP & Head of Technical Operations |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2024-06-28 |
| Fiscal Year End: | December |
| Full Time Employees: | 107 |